ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Vokes Discusses PARP Inhibitors in Lung Cancer

Everett E. Vokes, MD
Published: Saturday, Aug 02, 2014

Everett E. Vokes, MD, Giant of Cancer Care: Head and Neck Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses the administration of PARP inhibitors as treatments for patients with lung cancer.

Mutations in the BRCA1/2 genes have a detrimental impact on DNA repair. In many situations, these mutations are inherited; however, they can also be acquired, Vokes says. 

Further inhibition of the DNA repair mechanism through PARP inhibition results in antitumor activity. To accomplish this, PARP inhibitors are being examined in patients with lung cancer directly after a patient has received radiation. PARP inhibition is thought to augment the DNA damage already delivered by radiation, resulting in tumor cell death through a synthetic lethality, Vokes notes.

<<< View more from the 15th Annual International Lung Cancer Congress

Everett E. Vokes, MD, Giant of Cancer Care: Head and Neck Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses the administration of PARP inhibitors as treatments for patients with lung cancer.

Mutations in the BRCA1/2 genes have a detrimental impact on DNA repair. In many situations, these mutations are inherited; however, they can also be acquired, Vokes says. 

Further inhibition of the DNA repair mechanism through PARP inhibition results in antitumor activity. To accomplish this, PARP inhibitors are being examined in patients with lung cancer directly after a patient has received radiation. PARP inhibition is thought to augment the DNA damage already delivered by radiation, resulting in tumor cell death through a synthetic lethality, Vokes notes.

<<< View more from the 15th Annual International Lung Cancer Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x